Frederick John Livesey

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.

Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands.

Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019.

NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom.

Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway.

Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Cyclofluidic Ltd. is a British private company. The firm operates proprietary microfluidic drug discovery platform.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.

Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom.

NeuroSolutions Ltd. provides flexible and skilled services to biopharmaceutical companies with a fast turnaround time. The private company is based in Coventry, UK. The British company has a large portfolio of clients, ranging from small start-ups to multinational pharmaceutical companies, which validates their quality, reliability, speed, and discretion. The company was founded by Kevin Lee. NeuroSolutions was acquired by NeuroSolutions /Private Group/ from OncoSil Medical Ltd. on August 11, 2010 for $0.72 million.

Spliceor Ltd. is a British company founded in 2020 that specializes in gene therapies for aggressive cancers. The company is based in Cambridge, UK. The company's website is currently under construction, but more details are expected to follow.